Pilot study of home self-administration of subcutaneous depo-medroxyprogesterone acetate for contraception

被引:36
作者
Cameron, Sharon T. [1 ,2 ]
Glasier, Anna [2 ]
Johnstone, Anne [2 ]
机构
[1] NHS Lothian, Chalmers Sexual & Reprod Hlth Serv, Edinburgh EH3 9ES, Midlothian, Scotland
[2] Univ Edinburgh, Royal Infirm Edinburgh, Dept Reprod & Dev Sci, Edinburgh EH16 5SU, Midlothian, Scotland
关键词
Depo-medroxyprogesterone acetate; Contraception; Self-injection; Subcutaneous injection; Acceptability; DMPA; INJECTION; EFFICACY;
D O I
10.1016/j.contraception.2011.10.002
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Background: Subcutaneous depo-medroxyprogesterone acetate (DMPA-SC) offers the possibility of self-administration. Study Design: This is a pilot study of self-administration of DMPA-SC. Existing users of the intramuscular preparation (DMPA-IM) who wished to self-inject (n=64) were taught self-administration using DMPA-SC. The main outcome was the continuation rate of the method at 12 months compared to a control group of existing users of DMPA-IM (n=64) who continued to attend a clinic to receive the method. Women's satisfaction with the method and the proportion of self-injections given at correct time were also determined. Results: The 12-month discontinuation rate of the DMPA-SC group (12%) did not differ significantly from that of the DMPA-IM group (22%) (95% confidence intervals of 13%-33% and 6%-23% for DMPA-SC and DMPA-IM, respectively; p=.23). All self-injections were given within the appropriate interval. There was no significant difference in the proportion of women in either group who were satisfied with the method. Conclusion: Self-administration of DMPA-SC for contraception is feasible and is associated with similar continuation rates and satisfaction to clinician-administered DMPA-IM. (C) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码:458 / 464
页数:7
相关论文
共 22 条
[1]  
[Anonymous], 2004, Selected Practice Recommendations for Contraceptive Use
[2]   Change in bleeding patterns with depot medroxyprogesterone acetate subcutaneous injection 104 mg [J].
Arias, Raquel D. ;
Jain, John K. ;
Brucker, Cosima ;
Ross, Doug ;
Ray, Amrit .
CONTRACEPTION, 2006, 74 (03) :234-238
[3]   Self-administration with UniJect® of the once-a-month injectable contraceptive Cyclofem® [J].
Bahamondes, L ;
Marchi, NM ;
Nakagava, HM ;
de Melo, MLR ;
Cristofoletti, MD ;
Pellini, E ;
Scozzafave, RH ;
Petta, C .
CONTRACEPTION, 1997, 56 (05) :301-304
[4]   Patient and physician satisfaction with the Humulin®/Humalog® Pen, a new 3.0-mL prefilled pen device for insulin delivery [J].
Bohannon, NJV ;
Ohannesian, JP ;
Burdan, AL ;
Holcombe, JH ;
Zagar, A .
CLINICAL THERAPEUTICS, 2000, 22 (09) :1049-1067
[5]  
DORAI V, 1991, J PHARMACOL EXP THER, V258, P620
[6]  
Faculty of Sexual and Reproductive Healthcare, 2006, 1 PRESCR COMB OR CON
[7]  
Faculty of Sexual and Reproductive Healthcare, CLIN EFF UN GUID PRO
[8]   Strategies to improve adherence and acceptability of hormonal methods of contraception [J].
Halpern, Vera ;
Lopez, Laureen M. ;
Grimes, David A. ;
Gallo, Maria F. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2011, (04)
[9]   Contraceptive efficacy and safety of DMPA-SC [J].
Jain, J ;
Jakimiuk, AJ ;
Bode, FR ;
Ross, D ;
Kaunitz, AM .
CONTRACEPTION, 2004, 70 (04) :269-275
[10]   Pharmacokinetics, ovulation suppression and return to ovulation following a lower dose subcutaneous formulation of Depo-Provera® [J].
Jain, J ;
Dutton, C ;
Nicosia, A ;
Wajszczuk, C ;
Bode, FR ;
Mishell, DR .
CONTRACEPTION, 2004, 70 (01) :11-18